AveXis Reports Second Quarter 2017 Financial and Operating Results
AveXis on track to submit potency assay data to FDA in August
Conference call and webcast August 10 at 4:30 p.m. EDT
Chicago, Ill. (August 10, 2017) AveXis, Inc. (NASDAQ: AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today reported financial results for the second quarter ended June 30, 2017, recent corporate highlights and upcoming milestones.
It was another eventful quarter for AveXis with important progress made across multiple fronts, including alignment with the FDA on our GMP manufacturing process, presentation of closeout data from our Phase 1 study of AVXS-101 in SMA Type 1, the execution of licensing agreements for the use of AAV9 for two rare neurological monogenic disorders, and an increase in our cash position with the close of a recent public offering, said Sean Nolan, President and Chief Executive Officer of AveXis. Looking ahead,
we remain on track to have the data from the potency assay work ready to submit to the FDA as planned and to conduct an end-of-Phase 1 meeting with the FDA to further inform the regulatory pathway for AVXS-101.
Presented AVXS-101 research at the Annual Meeting of the American Academy of Neurology (AAN): On April 25, Jerry Mendell, M.D., principal investigator in the Phase 1 study of AVXS-101 in spinal muscular atrophy (SMA) Type 1 and Curran-Peters Chair of Pediatric Research, Professor of Pediatrics and Neurology at the Research Institute at Nationwide Childrens Hospital and The Ohio State University, presented results from the closeout of the study during a plenary session at AAN, including video evidence of children achieving motor milestones.